As an example of fundie interest the below is from Vishal...

As an example of fundie interest the below is from Vishal Teckchandani of Pengana Capital in LiveWire :

Telix Pharmaceuticals (ASX:TLX)

Nuclear medicine small-cap Telix Pharmaceuticals, whose Chief Medical Officer joined from Cochlear, is another company McDonald likes. Telix’s market cap is $280 million and it holds $35 million of cash in the bank.

The company is developing a pipeline of molecularly-targeted radiation products to image and treat renal, prostate and brain cancer and has attracted the attention of oncology societies in Europe and the U.S. McDonald added that the Food and Drug Administration gave the company a glowing review about the efficacy of their prostate cancer imaging product (illumet) and Telix is hoping for final approvals by year-end.

Telix’s prostate cancer imaging product has already been tested on 12,000 people at over 100 facilities and is currently being distributed by drug wholesaler Cardinal Health for US$300 per dose.

“When they get approval from the FDA the price increases to $4,000 per dose. It will certainly transform the businesses – its revenue run rate could increase to $200 million within 12 months of launch and it could generate $100 million of profit. This is extraordinary value but they’re not a one trick pony and have other treatments for the brain and kidney being developed.”

“When they get approval from the FDA the price increases to $4,000 per dose. It will certainly transform the businesses – its revenue run rate could increase to $200 million within 12 months of launch and it could generate $100 million of profit. This is extraordinary value but they’re not a one trick pony and have other treatments for the brain and kidney being developed.”